Get the Stockscreener App
4.89
6.27%
-0.29
Organogenesis Holdings Inc stock is traded at $4.89, with a volume of 277.02K.
It is down -6.27% in the last 24 hours and down -3.29% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$5.18
Open:
$5.18
24h Volume:
277.02K
Relative Volume:
0.17
Market Cap:
$619.33M
Revenue:
$433.14M
Net Income/Loss:
$4.95M
P/E Ratio:
136.97
EPS:
0.0357
Net Cash Flow:
$6.55M
1W Performance:
-7.96%
1M Performance:
-3.29%
6M Performance:
+19.88%
1Y Performance:
+60.23%
1-Day Range:
$4.81
$5.20
1-Week Range:
$4.81
$5.35
52-Week Range:
$2.6101
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
4.88 | 657.40M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
ZTS
Zoetis Inc
|
125.47 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.66 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
491.72 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis ... - Bluefield Daily Telegraph
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.ORGO - FinancialContent
Organogenesis drops as Medicare to pull skin substitute LCDs (update) - MSN
Organogenesis Holdings extends leases for Canton facilities through 2032 By Investing.com - Investing.com Australia
Organogenesis Holdings extends leases for Canton facilities through 2032 - Investing.com
Organogenesis Extends Long-Term Leases for Key Facilities - TipRanks
Organogenesis (NASDAQ:ORGO) Shares Gap DownTime to Sell? - MarketBeat
Organogenesis' (ORGO) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Organogenesis stock holds Buy rating at BTIG after CMS LCD decision - Investing.com
Organogenesis Initiates BLA Submission For ReNu In Knee Arthritis - Nasdaq
Organogenesis begins FDA rolling review for knee arthritis treatment By Investing.com - Investing.com Nigeria
Organogenesis starts rolling submission for ReNu allograft for knee arthritis - Seeking Alpha
Organogenesis stock rises after initiating FDA application for knee arthritis treatment By Investing.com - Investing.com South Africa
Organogenesis stock rises after initiating FDA application for knee arthritis treatment - Investing.com Nigeria
Organogenesis begins FDA rolling review for knee arthritis treatment - Investing.com
Organogenesis Announces Initiation of Biologics License Application for ReNu® - The Manila Times
Organogenesis Holdings Inc. Initiates Biologics License Application for ReNu® to Address Knee Osteoarthritis Pain - Quiver Quantitative
Biologic treatment for knee arthritis pain begins FDA license bid - Stock Titan
Gains Recap: Is Organogenesis Holdings Inc stock dividend yield sustainableWeekly Gains Report & Fast Gaining Stock Strategy Reports - moha.gov.vn
Net current asset value per share of Organogenesis Holdings, Inc. Class A – BER:2PQ - TradingView — Track All Markets
BTIG reiterates Organogenesis Holdings (ORGO) buy recommendation - MSN
Is Organogenesis Holdings Inc. stock a bargain at current levels2025 Momentum Check & Advanced Technical Analysis Signals - Улправда
Assenagon Asset Management S.A. Has $20.49 Million Stock Position in Organogenesis $ORGO - MarketBeat
Organogenesis (NASDAQ:ORGO) Shares Down 3.7% on Insider Selling - MarketBeat
Is Organogenesis Holdings Inc. stock dividend yield sustainableJuly 2025 Outlook & Breakout Confirmation Trade Signals - DonanımHaber
Is Organogenesis Holdings Inc. stock supported by strong cash flows2025 Price Targets & Free Safe Capital Growth Stock Tips - Улправда
Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf Sells 200,000 Shares - MarketBeat
Organogenesis Holdings Insider Sold Shares Worth $1,027,060, According to a Recent SEC Filing - marketscreener.com
Organogenesis Holdings Inc. (ORGO) director sells 200,000 shares - Stock Titan
How Organogenesis Holdings Inc. stock benefits from global expansion2025 Big Picture & Low Risk High Win Rate Stock Picks - Улправда
Organogenesis (NASDAQ:ORGO) Trading Up 8.5%Here's What Happened - MarketBeat
How Organogenesis Holdings Inc. stock reacts to oil pricesBreakout Watch & Consistent Return Strategy Ideas - Улправда
Recent Analysts’ Ratings Updates for Organogenesis (ORGO) - Defense World
Organogenesis (NASDAQ:ORGO) Earns “Buy” Rating from BTIG Research - Defense World
Organogenesis (NASDAQ:ORGO) Shares Gap UpTime to Buy? - MarketBeat
BTIG Research Reaffirms Buy Rating for Organogenesis (NASDAQ:ORGO) - MarketBeat
Organogenesis Plans to File Biologics Licenses Application for Knee Osteoarthritis Pain Therapy by 2025-End, Shares Up Pre-Bell - marketscreener.com
Organogenesis To File Rolling BLA For ReNu Following FDA Meeting - Nasdaq
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain - The Manila Times
Organogenesis stock soars after FDA meeting clears path for ReNu BLA - Investing.com Nigeria
Organogenesis to submit rolling BLA for knee osteoarthritis treatment - Investing.com India
Organogenesis to submit rolling BLA for knee osteoarthritis treatment By Investing.com - Investing.com Australia
Organogenesis announces successful FDA meeting and plan to file BLA for ReNu® - marketscreener.com
Organogenesis (Nasdaq: ORGO) to file BLA for ReNu knee OA pain by Dec. 2025 - Stock Titan
December 2025's Top Penny Stocks With Promising Potential - simplywall.st
Organogenesis: High-Tech Skin Substitute Company On Sale (NASDAQ:ORGO) - Seeking Alpha
Investors in cash trouble should check out Organogenesis Holdings Inc (ORGO) - setenews.com
Why analysts remain bullish on Organogenesis Holdings Inc. stockEarnings Beat & Technical Entry and Exit Alerts - Newser
Is Organogenesis Holdings Inc. stock attractive for income investorsMarket Movers & Technical Buy Zone Confirmation - Newser
Organogenesis Holdings Inc. (NASDAQ:ORGO) Surges 29% Yet Its Low P/S Is No Reason For Excitement - 富途牛牛
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):